RPG Life Sciences API carve-out: ₹700 cr plan in 2026

What the company completed on August 15, 2026

RPG Life Sciences Limited has completed the transfer of its Active Pharmaceutical Ingredients (API) business to RPG Active Pharma Limited, a wholly owned subsidiary. The transfer became effective on August 15, 2026, and was executed on a slump sale basis. The company disclosed the completion through a letter dated August 15, 2026, addressed to the National Stock Exchange of India Limited and BSE Limited. The update was made under a SEBI Regulation 30 filing. The company had earlier informed exchanges on July 29, 2026, about the execution of the Business Transfer Agreement. The restructuring moves the API operations into a dedicated subsidiary structure. RPG Life Sciences also described the change as positioning the API business as a focused platform.

Board approvals and the July 2026 agreements

On July 29, 2026, the Board approved the slump sale and the company signed a strategic investment agreement with healthcare private equity firm InvAscent. The Business Transfer Agreement executed in July laid the groundwork for shifting the API business into RPG Active Pharma. The sequence matters because it separates decision-making and documentation from the effective operational transfer date. The company’s stock exchange communication indicates the transfer is now complete, rather than a proposed reorganisation. Alongside the carve-out, the company highlighted an external capital partnership. That partnership is structured through investment tranches tied to milestones, growth opportunities, and capital deployment plans.

InvAscent investment: stake and funding commitments

Funds managed by InvAscent are set to invest up to ₹243 crore in RPG Active Pharma in the first tranche. This initial tranche is for a 40% stake in RPG Active Pharma on a fully diluted basis, as described by the company. Beyond the first tranche, RPG Life Sciences and InvAscent have committed to invest up to ₹700 crore in RPG Active Pharma in tranches. The company indicated the infusion will be phased and linked to agreed milestones and growth opportunities. The overall structure effectively pairs a carve-out with a defined capital plan. The stated objective is to build a larger, standalone API platform under RPG Active Pharma.

Acquisition of Actis Generics for ₹80 crore

RPG Active Pharma has acquired a 100% equity stake in Actis Generics Private Limited for ₹80 crore. Actis Generics is described as a Visakhapatnam-based bulk drug intermediates manufacturer and an API manufacturer located in Visakhapatnam. The deal is positioned as strengthening manufacturing footprint. The company also referred to the transaction as an all-cash deal in its earlier communications. The acquisition sits alongside the carve-out and funding plan, indicating that RPG Active Pharma is being built not only as a transferred business but also through inorganic expansion. This combination of transfer plus acquisition provides a clearer operating perimeter for the subsidiary.

API revenue base disclosed for FY26

RPG Life Sciences disclosed that its API business generated revenue of ₹95.06 crore during FY26. The company also stated this represented about 13.5% of its total turnover. The context provided alongside the API share implies total revenue of ₹707.52 crore for FY26 (derived from the figures cited: ₹95.06 crore API revenue versus ₹707.52 crore total revenue). While the API business is not the majority of the company’s turnover, the carve-out indicates a strategic decision to run it as a separate, capital-backed platform. The FY26 disclosure provides investors a clear starting point to assess the scale being transferred into RPG Active Pharma.

Leadership movement aligned to the carve-out

RPG Life Sciences also announced the resignation of Deepak Shukla as Chief Executive - API Business, effective August 14, 2026. The company stated that Shukla will assume the role of Chief Executive Officer at RPG Active Pharma Limited starting August 15, 2026. The date alignment matches the effective date of the business transfer. This leadership shift is consistent with moving operational accountability into the subsidiary. It also signals that RPG Active Pharma is being run as a distinct platform, rather than as a carve-out on paper alone.

Disclosures and confirmations to stock exchanges

The company’s communication to NSE and BSE confirms the completion of the transaction and the effective date. The disclosure references the prior July 29, 2026 intimation that the Business Transfer Agreement had been executed. Rajesh Shirambekar, Head - Legal & Company Secretary, is cited as confirming that the move consolidates API operations within the subsidiary structure. The combination of a Board-approved transaction, a signed agreement, and the stated effective date provides a clear compliance trail. These filings are relevant for investors tracking corporate actions and subsidiary-level capital raising.

Slump sale basis and the reported consideration

The transfer was executed on a slump sale basis as a going concern. Separately, a July 30, 2026 reference indicates the API business was being spun off to RPG Active Pharma for ₹33.55 crore. The completion date later confirmed by the company is August 15, 2026. Investors typically track both the consideration and the effective date to understand the accounting and operational cutover. In this case, the company’s subsequent filing focuses on completion and effectiveness, following the earlier announcements.

Key facts at a glance

Why the restructuring matters for investors

The transaction places the API business in a separate corporate vehicle with its own funding pathway. The disclosed investment structure involves a defined first tranche and an overall committed funding envelope that could scale the API platform beyond its FY26 revenue base. The subsidiary also completed an acquisition to strengthen manufacturing footprint, indicating the platform is intended to expand. From a disclosure perspective, the company has provided a clear timeline: Board approval and agreement in July, leadership transition on August 14-15, and business transfer effectiveness on August 15. The SEBI Regulation 30 filing and letters to NSE and BSE create formal confirmation of completion.

What to watch next based on stated steps

The company has indicated that investments of up to ₹700 crore will be infused in phases linked to milestones, growth opportunities and capital deployment plans. Investors will likely track tranche timing and any further subsidiary-level actions related to the InvAscent partnership. Developments related to Actis Generics integration may also be relevant given the ₹80 crore purchase and the focus on manufacturing footprint. For now, the confirmed next phase is execution of the planned tranches under the investment commitment framework already announced.